<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04722068</url>
  </required_header>
  <id_info>
    <org_study_id>1331-Kin</org_study_id>
    <nct_id>NCT04722068</nct_id>
  </id_info>
  <brief_title>Regeneron 1331 Kinetics Sub-Study HoFH</brief_title>
  <official_title>A Kinetic Study Investigating Lipoprotein Metabolism Before and After the Administration of REGN1500, an ANGPTL3 Inhibitor, in Patients With Homozygous Familial Hypercholesterolemia. A Sub-study for Subjects Enrolled in the R1500-CL-1331 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the lipoprotein kinetics of subjects enrolled in the R1500-CL-1331 clinical trial&#xD;
      (NCT02265952) to assess the mechanism by which the evinacumab may affect lipid levels in HoFH&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects enrolled in the R1500-CL-1331 clinical trial (NCT0226595) will participate in a&#xD;
      study visit before and after administration of the ANGPTL3 inhibitor REGN1500, evinacumab)&#xD;
      for the evaluation of its effect on lipoprotein kinetics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2016</start_date>
  <completion_date type="Actual">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">November 30, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional catabolic rate (FCR) pools/day</measure>
    <time_frame>completion of study, average of 8 weeks</time_frame>
    <description>First visit to be performed prior to first evinacumab administration; second visit to be performed approximately 4-6 weeks after evinacumab i.v. administration. About 8 weeks between the 2 visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Production rate (PR) of lipoproteins mg/kg/day</measure>
    <time_frame>completion of study, average of 8 weeks</time_frame>
    <description>First visit to be performed prior to first evinacumab administration; second visit to be performed approximately 4-6 weeks after evinacumab i.v. administration. About 8 weeks between the 2 visits.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Hypercholesterolemia, Familial</condition>
  <arm_group>
    <arm_group_label>Volunteers with known HoFH and particpated in R1500-CL-1331 clinical trial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Kinetics test</intervention_name>
    <description>Subjects will participate in two study visits to evaluate lipoprotein kinetics before and after administration of evinacumab.</description>
    <arm_group_label>Volunteers with known HoFH and particpated in R1500-CL-1331 clinical trial</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility criteria:&#xD;
&#xD;
        -Eligibility will be made based on the data collected at the screening visit of the&#xD;
        R1500-CL-1331 protocol. Subjects must meet all inclusion/exclusion criteria for eligibility&#xD;
        of that study to be eligible to participate in this sub-study. Below is the eligibility&#xD;
        criteria for R1500-CL-1331.&#xD;
&#xD;
        Inclusion:&#xD;
&#xD;
          -  Men and women 18 years or older at the time of the screening visit&#xD;
&#xD;
          -  Diagnosis of HoFH by one of the following:&#xD;
&#xD;
               1. Documented mutation or mutations in both LDLR alleles&#xD;
&#xD;
               2. Documented presence of homozygous or compound heterozygous mutations in Apo B&#xD;
                  and/or PCSK9&#xD;
&#xD;
               3. Documented skin fibroblast LDLR activity &lt;20% of normal&#xD;
&#xD;
          -  Willing to consistently maintain his/her usual diet for the duration of the study&#xD;
&#xD;
          -  Willing and able to comply with clinic visits and study-related procedures&#xD;
&#xD;
          -  Provide signed informed consent&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Background medical LMT (if applicable) that has not been stable for at least 4 weeks&#xD;
             (6 weeks for fibrates) prior to the screening visit (week -2) (unless participating in&#xD;
             the run-in period to stabilize)&#xD;
&#xD;
          -  Having undergone lipid apheresis within 4 weeks prior to the screening visit (week -2)&#xD;
             (unless participating in the run-in period to wash out)&#xD;
&#xD;
          -  Presence of any clinically significant uncontrolled endocrine disease known to&#xD;
             influence serum lipids or lipoproteins. Note: Patients on thyroid replacement therapy&#xD;
             can be included if the dosage of thyroxine has been stable for at least 12 weeks prior&#xD;
             to screening visit (week -2)&#xD;
&#xD;
          -  Use of systemic corticosteroids, unless used as replacement therapy for&#xD;
             pituitary/adrenal disease with a stable regiment for at least 6 weeks prior to the&#xD;
             screening visit (week -2) Note: Topical, intra-articular, nasal, inhaled, and&#xD;
             ophthalmic steroid therapies are not considered as &quot;systemic&quot; and are allowed&#xD;
&#xD;
          -  History of a myocardial infarction, unstable angina leading to hospitalization,&#xD;
             coronary bypass graft surgery, percutaneous coronary intervention, uncontrolled&#xD;
             cardiac arrhythmia, carotid surgery or stenting, stroke, transient ischemic attack,&#xD;
             carotid revascularization, endovascular procedure or surgical intervention for&#xD;
             peripheral vascular disease within 3 months prior to the screening visit (week -2)&#xD;
&#xD;
          -  Known history of HIV and a CD4 count less than 350c/mL Note: Patients with a history&#xD;
             of HIV can be included, as long as they:&#xD;
&#xD;
               1. have a CD4 count greater than 350c/mL;&#xD;
&#xD;
               2. have an undetectable viral load for at least 12 months prior to screening;&#xD;
&#xD;
               3. have no opportunistic infections or active tuberculosis for at least 12 months&#xD;
                  prior to screening;&#xD;
&#xD;
               4. are not receiving prophylaxis for opportunistic infections; and have been on&#xD;
                  stable antiretroviral therapy for at least 12 months prior to screening&#xD;
&#xD;
          -  Use of another investigational drug or therapy within 30 days or at least 5 half-lives&#xD;
             (whichever is longer) prior to screening visit (week -2). Includes patients who were&#xD;
             involved in a prior clinical trial and are not sure of their treatment assignment.&#xD;
&#xD;
          -  Previous participation in any clinical trial of REGN1500&#xD;
&#xD;
          -  Conditions/situation such as:&#xD;
&#xD;
               1. Any clinically significant abnormality identified at the time of screening that,&#xD;
                  in the judgement of the investigator or any subinvestigator, would preclude safe&#xD;
                  completion of the study or constrain endpoints assessment; eg. major systemic&#xD;
                  diseases, patients with short life expectancy&#xD;
&#xD;
               2. Patient considered by the investigator or any subinvestigator as inappropriate&#xD;
                  for this study for any reason, eg: deemed unable to meet specific protocol&#xD;
                  requirements, such as scheduled visits. Deemed unable to tolerate injections as&#xD;
                  per the patient or the investigator. Investigator or any subinvestigator,&#xD;
                  pharmacist, study coordinator, other study staff or relative thereof directly&#xD;
                  involved in the conduct of the protocol, etc. Presence of any other conditions&#xD;
                  (eg, geographic or social), either actual or anticipated, that the investigator&#xD;
                  feels would restrict or limit the patient's participation for the duration of the&#xD;
                  study&#xD;
&#xD;
          -  Laboratory findings during screening period:&#xD;
&#xD;
               1. Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody&#xD;
&#xD;
               2. Positive serum beta-human chorionic gonadotropin or urine pregnancy test in women&#xD;
                  of childbearing potential&#xD;
&#xD;
               3. Triglycerides greater than 400 mg/dL ( &gt;3.95 mmol/L) (1 repeat lab is allowed)&#xD;
&#xD;
               4. Estimated glomerular filtration rate &lt;30 mL/min/1.73m^2 according to 4-variable&#xD;
                  Modification of Diet in Renal Disease Study equation (calculated by central lab)&#xD;
&#xD;
               5. Alanine amintransferase (ALT) or aspartate aminotransferase (AST) &gt;3 x the upper&#xD;
                  limit of normal (ULN) (1 repeat lab is allowed)&#xD;
&#xD;
               6. Creatine phosphokinase (CPK) &gt;3 x ULN (1 repeat lab is allowed)&#xD;
&#xD;
          -  Known hypersensitivity to monoclonal antibody therapeutics&#xD;
&#xD;
          -  History of hypersensitivity reaction to doxycycline or similar compound&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Sexually active men, or women of childbearing potential, who are unwilling to utilize&#xD;
             adequate contraception for at least 6 months after the last dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Cuchel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Vascular Medicine Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <state>AZ</state>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipid metabolism</keyword>
  <keyword>Homozygous Familial Hypercholesterolemia</keyword>
  <keyword>Evinacumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

